Liistro Francesco, Falsini Giovanni, Bolognese Leonardo
Cardiology Department, San Donato Hospital, Arezzo, Italy.
Ital Heart J. 2003 Oct;4(10):668-76.
Contrast-induced nephropathy (CIN) is the third cause of acquired acute renal dysfunction. The risk of developing a contrast media (CM)-induced nephropathy depends on their different physicochemical properties. The iso-osmolality of third generation CM lowers the incidence of CM-related renal dysfunction. The tubular effect of CM and the hemodynamic changes induced by CM in the renal medulla are thought to be the main mechanisms of CIN. The percentage of patients at risk has been estimated to range between 3.5 and 15.5% depending on the presence of a preexisting impaired renal function, diabetes mellitus, congestive heart failure, and hypertension and on the volume of contrast used. Currently, only hydration is a generally accepted method of reducing the risk of CIN, and further trials are needed to prove the effectiveness of other potential prophylactic treatments. Alternatives to ordinary CM, such as carbon dioxide or gadolinium chelates, can be used in patients at high risk of CIN undergoing peripheral diagnostic or interventional procedures, thus reducing the occurrence of CIN.
对比剂肾病(CIN)是获得性急性肾功能障碍的第三大病因。发生对比剂(CM)所致肾病的风险取决于其不同的物理化学性质。第三代CM的等渗性降低了CM相关肾功能障碍的发生率。CM的肾小管效应以及CM在肾髓质诱导的血流动力学变化被认为是CIN的主要机制。根据是否存在既往肾功能受损、糖尿病、充血性心力衰竭和高血压以及所用对比剂的量,估计有风险的患者百分比在3.5%至15.5%之间。目前,只有水化是普遍接受的降低CIN风险的方法,还需要进一步试验来证明其他潜在预防治疗的有效性。普通CM的替代品,如二氧化碳或钆螯合物,可用于接受外周诊断或介入操作且CIN风险高的患者,从而减少CIN的发生。